NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000002098

Registered date:31/07/2009

Natural Compound Curcumin as a Novel Therapy for Congestive Heart Failure: Effects of Curcumin on Left Ventricular Diastolic Function in Hypertensive Heart Disease

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedHypertensive Heart Disease
Date of first enrollment2009/08/01
Target sample size100
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Curcumin 2g/day p.o. Placebo 2g/day p.o.

Outcome(s)

Primary OutcomeConventional Doppler indices of left ventricular diastolic function including 1) Transmitral E/A ratio, 2) Decerelation time, 3) Pulmonary venous S/D ratio, etc Tissue Doppler indices of left ventricular diastolic function including 4) E/E' ratio, etc
Secondary Outcome1) Symptons 2) Activity (Mets) 3) Blood pressure, pulse rate, and body mass index 4) Blood analysis including BNP concentration and urinalysis 5) Plasma Curcumin concentration 6) Chest X-p 7) Electrocardiogram 8) Echocardiography: left ventricular (LV) end-diastolic dimension, LV end-systolic demension, LV ejection fraction, left atrial demension, intraventricular septum thickness, LV posterior wall thickness, transmitral E and A wave velosity, pulmonary S and D wave velosity, and tissue Doppler early diastolic mitral annular velosity, etc

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum80years-old
GenderMale and Female
Include criteria
Exclude criteria1) Chronic atrial fibrillation 2) Unstable angina, recent (< 3 months) myocardial infarction, severe coronary heart disease (left main trunk or 3 vessel disease), and recent (=< 3 months) or planned (=< 6 months) AC bypass surgery / PCI 3) Severe arrhythmia (sustained ventricular tachycardia, ventricular fibrillation, and severe bradycardia with an indication of pacemaker implantation 4) Moderate or severe valvular diseases 5) Cardiomyopathy or progressive myocarditis 6) Severe respiratory diseases 7) Cardiogenic shock or systolic blood pressure < 80 mmHg 8) Renal failure (Cre >= 4.0 mg/dL or dialysis) 9) Severe liver dysfunction or liver cirrhosis 10) Recent (< 3 months) cerebrovascular disease 11) Malignancy 12) Poorly controlled diabetes (HbA1c >= 8.0%) 13) Anemia (Hb < 6.0 mg/dL) 14) Use of steroid 15) Past history of Curcumin allergy 16) Pregnancy, nursing, or a wish for pregnancy within 6 months 17) etc

Related Information

Contact

public contact
Name Koji Hasegawa
Address 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan Japan
Telephone 075-641-9161
E-mail koj@kuhp.kyoto-u.ac.jp
Affiliation National Hospital Organization Kyoto Medical Center Division of Translational Research
scientific contact
Name Koji Hasegawa
Address 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan Japan
Telephone 075-641-9161
E-mail
Affiliation National Hospital Organization Kyoto Medical Center Division of Translational Research